A series of (mercaptoaroyl)amino acids and related compounds was synthesized and tested for ability to inhibit angiotensin converting enzyme (ACE). The most active compound was N-(3-chloro-2-mercaptobenzoyl)-N-cyclopentylglycine, having an in vitro I50 = 0.28 microM. Substitution of the aromatic 3-position by small polar groups enhanced ACE inhibitory activity, whereas bulky groups diminished it. Alteration of the beta relationship between the mercaptan and amide carbonyl or masking of the thiol by acylation reduced activity. Replacement of the thiol by nitro, hydroxy, or carboxy gave compounds lacking ACE inhibitory activity.
Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of type (I) are constituted by three distinct building blocks: an aromatic template a, a conformation modulator b and a spacer moiety c as detailed in the description and the claims. Macrocycles of type (I) are readily manufactured by parallel synthesis or combinatorial chemistry. They are designed to interact with specific biological targets. In particular, they show agonistic or antagonistic activity on the motilin receptor (MR receptor), on the serotonin receptor of subtype 5-HT2B (5-HT2B receptor), and on the prostaglandin F2 • receptor (FP receptor). They are thus potentially useful for the treatment of hypomotility disorders of the gastrointestinal tract such as diabetic gastroparesis and constipation type irritable bowl syndrome; of CNS related diseases like migraine, schizophrenia, psychosis or depression; of ocular hypertension such as associated with glaucoma and preterm labour.
Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of formulae Ia and Ib are constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. These macrocycles Ia and Ib are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being the agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), ion channels and signal transduction pathways. In particular, these macrocycles act as antagonists of the motilin receptor, the FP receptor and the purinergic receptors P2Y
1
, as modulators of the serotonin receptor of subtype 5-HT
2B
, as blockers of the voltage-gated potassium channel K
v
1.3 and as inhibitors of the β-catenin-dependent “canonical” Wnt pathway. Thus they are showing great potential as medicaments for a variety of diseases.
PROCESS FOR PRODUCING POLYMER TERMINATED WITH OPTIONALLY PROTECTED FUNCTIONAL GROUP
申请人:KURARAY Co. LTD.
公开号:EP0704460A1
公开(公告)日:1996-04-03
A process for producing polymers having terminal functional group which may be protected, comprises polymerizing a radical-polymerizable monomer with a polymerization initiator comprising at least one member selected from the group (A) consisting of thio-S-carboxylic acids represented by the following general formula (1) and dithiocarboxylic acids represented by the following general formula (2) and at least one member selected from the group (B) consisting of polysulfides represented by the following general formula (3), polysulfides represented by the following general formula (4) and sulfoxides:
wherein R¹ represents a hydrocarbon group which may have a substituent including functional group;
wherein R² represents a hydrocarbon group which may have a substituent including functional group;
wherein R³ and R⁴ each represents a hydrocarbon group which may have a substituent including functional group and n is an integer of 2 or more; and
R⁵- (S)m- R⁶ (4)
wherein R⁵ and R⁶ each represents a hydrocarbon group having a functional group and m is an integer of 2 or more. This process can produce polymers with which functional groups have been introduced into one end or both ends thereof, irrespective of the rate of polymerization or the degree of polymerization of the polymer that forms.